SunGen gets FDA nod for lidocaine ointment

SunGen Pharma, has received the Food and Drug Administration’s approval for lidocaine ointment, in a dosage strength of 5%.

It is used for production of anesthesia of accessible mucous membranes of the oropharynx. It is also useful as an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin, and insect bites.

The product has a market value of about $60 million, the company said.

“Our high-quality development expertise and capability is now expanded to topical dosage forms and is further demonstrated by the short approval timeline. We will continue to focus on development of highly selective products that are niche and high barrier to entry with high value added to United States and Asian markets,” said Jim Huang, co-founder and co-ceo of the company.